MedTrace Logo

Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

NCT03715023 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-06-12

No results posted yet for this study

Summary

This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus multiplies. PC786 is an inhaled medicine. Participants will be treated with SoC treatment (e.g. oral ribavirin and/or IV immunoglobulin), half of the participants will receive PC786 in addition and half will receive a placebo treatment. The study will take place at multiple sites in UK and will include approximately 30 participants. The maximum study duration will be about 4 weeks.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

PC786

PC786 suspension for inhalation

DRUG

Placebo

Placebo solution for inhalation

DRUG

SOC

Standard treatment for RSV infection at study site

Sponsors & Collaborators

  • Pulmocide Ltd

    lead INDUSTRY

Principal Investigators

  • Alison Murray · Pulmocide Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2019-02-19
Completion
2019-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03715023 on ClinicalTrials.gov